Corient Private Wealth
VRTX icon

Corient Private Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Corient Private Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.7M Buy
112,098
+25,606
+30% +$11.3M 0.07% 234
2026
Q1 		$38.2M Sell
86,492
-128,216
-60% -$59.8M 0.05% 281
2025
Q4 		$92.9M Buy
214,708
+112,977
+111% +$48.7M 0.06% 258
2025
Q3 		$39.9M Sell
101,731
-1,085
-1% -$453K 0.06% 268
2025
Q2 		$45.8M Sell
102,816
-3,734
-4% -$1.72M 0.06% 245
2025
Q1 		$51.7M Sell
106,550
-6,596
-6% -$3.07M 0.08% 215
2024
Q4 		$45.2M Sell
113,146
-16,119
-12% -$7.47M 0.07% 244
2024
Q3 		$60.1M Sell
129,265
-25,555
-17% -$12.3M 0.09% 207
2024
Q2 		$72.6M Buy
154,820
+2,281
+1% +$990K 0.13% 166
2024
Q1 		$63.6M Buy
152,539
+71
+0% +$30K 0.11% 188
2023
Q4 		$62M Sell
152,468
-7,776
-5% -$2.87M 0.11% 185
2023
Q3 		$55.7M Sell
160,244
-12,059
-7% -$4.22M 0.13% 172
2023
Q2 		$60.6M Sell
172,303
-3,362
-2% -$1.13M 0.14% 155
2023
Q1 		$55.3M Buy
175,665
+30,339
+21% +$9.1M 0.15% 149
2022
Q4 		$42M Buy
+145,326
New +$44.3M 0.15% 155

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Corient Private Wealth's VRTX Position: Q2 2026 in Review

Corient Private Wealth increased its Vertex Pharmaceuticals (VRTX) stake by 30% in Q2 2026, buying an estimated $11.3M and bringing the position to 112,098 shares worth $55.7M. The position accounts for 0.07% of the portfolio, ranked #234.

Corient Private Wealth first reported a position in VRTX in Q4 2022 and has held it in 15 quarters since. The position peaked at $92.9M in Q4 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Corient Private Wealth held 112,098 shares of Vertex Pharmaceuticals worth $55.7M as of Q2 2026.
  • Corient Private Wealth bought 25,606 Vertex Pharmaceuticals shares in Q2 2026, an estimated $11.3M.
  • Vertex Pharmaceuticals made up 0.07% of Corient Private Wealth's portfolio in Q2 2026, its #234 holding.
  • Corient Private Wealth first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Corient Private Wealth's Vertex Pharmaceuticals position peaked at $92.9M in Q4 2025.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.